Anesthesia for Valvular Heart Surgery

Download Report

Transcript Anesthesia for Valvular Heart Surgery

Anesthesia for Valvular Heart Surgery
Charles E. Smith, MD
Professor of Anesthesia
Director, Cardiothoracic Anesthesia
MetroHealth Medical Center
Case Western Reserve University
Objectives
• Pathophysiology
– Aortic valve: AS, AI
– Mitral valve: MS, MR
– Tricuspid valve: TR
• Hemodynamic Goals
• Anesthetic management
Aortic Stenosis
•
May occur at 3 levels:
1. Valvular
2. Subvalvular
3. Supravalvular
Valvular Aortic Stenosis
1. Calcification + fibrosis of normal tricuspid
valve- very common
2. Calcification + fibrosis of congenital
bicuspid AV
3. Rheumatic- uncommon since antibiotics
Aortic Stenosis
•
•
•
•
Normal AVA: 2-4 cm2
Severe AS: AVA < 1cm2
If normal LV- mean PG > 50 mmHg
If poor LV function- mean PG may be low!
Pathophysiology of Aortic Stenosis
• Chronic LV pressure overload
• Concentric LVH to ↓ wall stress
• LVH → ↓ diastolic compliance, ↓ coronary
blood flow + imbalance of MVO2 supplydemand
• ↓ diastolic compliance → ↑LVEDP + LVEDV
• Myocardial ischemia bc LVH, ↑ wall stress,
↓ diastolic coronary perfusion + ↓ coronary
flow reserve
Hemodynamic Goals: AS
• SR is crucial. Cardiovert SVTs promptly
• Optimal HR 60-80. Tachycardia → ischemia +
ectopy. Bradycardia → low CO due to fixed SV
• Adequate preload essential but difficult to predict
bc diastolic dysfunction [TEE useful]
• Maintain contractility. Avoid myocardial
depressants
• Treat hypotension promptly- phenylephrine,
volume, Trendelenburg
AS: Considerations
• Drugs to maintain CPP:
– Phenylephrine
– Norepinephrine
• Atrial kick – crucial. HR 60-80 preferred
• Spinal + epidural anesthesia poorly tolerated if
 preload or  HR
AS: Management
• Premed: young+ anxious get benzos.
Frail + elderly  dose (or avoid)
• Intraop: std monitoring + preinduction
art line.
• Resting HR 60-80. Avoid myocardial
depressants
• CVP, PAC, TEE- routine for optimal
management
AS: Weaning from Bypass
• Thick, hypertrophied heart may be difficult
to protect- stone heart still occurs (rare)
• Noncompliant LV dependent on stable
rhythm
• Inotropes if preop LV dysfunction
• Dynamic subaortic or cavitary obstruction
after AVR if septal LVH
• Tx w volume, β-blockers. Rarely need
myomectomy [inotropes worsen obstruction]
Septal LVH with SAM. Tx= volume + beta-blockers
Aortic Regurgitation: Etiology
1. Aortic root dilatation- HTN, ascending
aorta dissection, cystic medial necrosis,
Marfans, syphilitic aortitis, ankylosing
spondylitis, osteogenesis imperfecta
2. Deformed + thickened cusps- rheumatic,
IE, bicuspid valve
3. Cusp prolapse- dissection
Horse kick to upper chest with severe AI.
The RCC was torn from the STJ
Pathophysiology: Chronic AR
• Asymptomatic for many years
• LV volume + pressure overload occurs
• LV maintains systolic fct by dilation +
↑ compliance
• LV decompensates at later stages w
↑ LVEDP + LVEDV→ CHF, arrhythmias,
sudden death
Pathophysiology: Acute AR
• LV unable to dilate acutely
• LV volume overload occurs
• ↑ LVEDP + LVEDV→ acute pulmonary
edema
• Emergency surgery often needed
Hemodynamic Goals: AR
•
•
•
•
•
Optimal HR= 90.
Avoid bradycardia- ↑ regurg
Avoid high afterload
SNP preferred
Acute AR- often need inotropes +
vasodilator [epi+ SNP/milrinone]
• IABP- contraindicated
Anesthetic Management: AR
•
•
•
•
•
Premed w benzos
Routine monitoring: art line, CVP, PAC
TEE beneficial
Narcotic based technique if impaired LV
If acute AR: RSI w ketaminesuccinylcholine
• Inotropes if acute AR or preop LV
dysfunction
Mitral Stenosis
• Usually rheumatic- thickening, calcification
+ fusion of MV leaflets + commissures
• May be combined w MR + AR
• Surgery if MVA < 1 cm2 w NYHA class III
or IV dyspnea [or embolus- LAA clot]
MS- Pathophysiology
• Pressure gradient between LA + LVprevents LV filling
• Pulmonary HTN w ↑ LAP
• ↑ LAP → LAE, atrial arrhythmias (Afib)
• Pulm HTN → RV dysfct, RVE, TR [may
need TV repair]
• LV dysfct uncommon unless CAD
MS: Hemodynamic Goals
• Preserve SR, if present
• Avoid tachycardia which ↓ diastolic filling
of LV + worsens MS
• Avoid factors which worsen pulmonary
HTN- hypercarbia, acidosis, hypothermia,
sympathetic nervous system activation,
hypoxia
Anesthetic Management: MS
• Premed: benzos to avoid tachycardia
• If pulm HTN- supplemental O2
• Control of HR- β blockers, digoxin, CEB,
amiodarone
Intraop Management: MS
• Std monitors + CVP, PAC, TEE
• PAP underestimates LVEDP + LVEDV
• Esmolol:
– single most useful drug with severe MS, even
if CHF + pulmonary edema
– 10-20 mg bolus; 50-100 mcg/kg/min
• N2O avoided bc effects on pulm HTN
• Panc avoided bc tachycardia
Weaning from Bypass: MS
• MV replacement- hemodynamics usually
improved bc obstruction to LV filling
resolved
• If preop pulm HTN + RV dysfctmay need milrinone or nitric oxide
Mitral Regurgitation: Etiology
1. Myxomatous degeneration
(most common)
2. Ischemic (functional)- papillary muscle
dysfunction, annular dilatation,
LV dysfct + tethering
3. Infective endocarditis
4. Trauma
Papillary muscle rupture after blunt trauma
MR- Pathophysiology
•
•
•
•
Volume overload of LV→ LVE, LAE
LA can massively dilate
Atrial arrhythmias with LAE
Dilated LV decompensates at later stages
w  LVEDV
Chronic MR. Dilated LA w normal LAP
Chronic MR. Dilated LA
w normal LAP
Acute MR. Small LA with ↑ ↑ LAP+ pulmonary edema
Severity of MR
1. Pressure gradient between LA + LV
2. Size of regurgitant orifice (ERO)
3. Duration of ventricular systole
Hemodynamic Goals- MR:
• Vasodilators: NTG, SNP - ↓ afterload +
regurgitant fraction + ↑ forward flow
• High normal HR to ↑ time of ventricular
systole
• Maintain contractility
Anesthetic Management MR:
• MV repair (v. replacement)
– preserved papillary muscle + chordae
– enhanced LV function
– requires TEE to assess repair
• LV dysfct unmasked after MV surgery bc
LV cannot offload into LA
• May need inotropes + vasodilators
Tricuspid Regurgitation
• Primary: rheumatic, IE, carcinoid,
Ebstein’s, trauma
• Secondary: chronic RV dilatation, often w
MV disease
Flail TV after blunt trauma
TR- Pathophysiology
• RV + RA overloaded + dilated
• RA v compliant so RAP rises only w end
stage disease
• Pulm HTN due to MV disease↑ RV afterload + worsens TR
• RVE → paradoxical motion LV septum w
imapired LV filling + compliance
• Right heart failure: hepatomegaly, ascites
TR- Hemodynamic Goals
• If secondary to MV- treat left heart lesion
• Avoid pulm HTN + high PVR
• Normal to high preload for RV stroke
volume
• Hypotension treated w inotropes + volume
bc vasoconstrictors may worsen pulm
HTN
TR- Anesthetic Management
• Premed- benzos
• Std monitors + art line, CVP, TEE
• PAC if pulm HTN + MV pathology; but CO
overestimated w severe TR. May be
impossible to float Swan
• Weaning from CPB: if preop RV
dysfunction/ dilation- inotropes, inodilators,
vasodilators, nitric oxide
Summary- I
• Knowledge of patient + extent of valvular
heart disease
• Functional + hemodynamic status
• Co-morbidities
• Planned surgery: cannulation sites, repair
vs replacement, minimally invasive vs full
bypass.
• Inotropes, vasodilators, vasopressors,
infusion pumps
Summary- II
• Understand pathophysiology of lesions +
hemodynamic goals: AS, AR, MS, MR, TR
• Monitoring: standard + invasive +TEE
• Anesthetic technique: most can be used
safely.
• Adjustment of dosages more important
than adhering to a rigid anesthetic
technique.